Suzhou Ribo Life Science Co. Ltd. Class H
HHKEX:693848.00
HKD
-4.65
(-8.83%)
ISIN
CNE100007DS6
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Liang Zicai
- Full Time Employees
- 407
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- No.168, Yuanfeng Road Kunshan JS China 215300
- IPO Date
- Jan 9, 2026
- Website
- ribolia.com
- Similar Companies
- Business
- Suzhou Ribo Life Science Co., Ltd. is a biopharmaceutical company specializing in RNA interference (RNAi) technologies and oligonucleotide therapeutics, with a focus on cardiovascular, metabolic, renal, and liver diseases. The company develops and commercializes siRNA, antisense, and aptamer drugs, supported by an integrated platform that spans discovery, optimization, delivery, preclinical and clinical development, manufacturing, and commercialization. Based in Suzhou, China, it operates with a global development and collaboration footprint and aims to translate RNAi-based medicines into clinically meaningful therapies. Main products and services: - Core siRNA therapeutics: RiboLife siRNA drug candidates targeting thrombotic and other disease pathways; development across multiple indications, including cardiovascular and metabolic conditions; pipeline includes several assets advancing in clinical trials. - Antisense and aptamer modalities: oligonucleotide-based therapies leveraging sequence-specific mechanisms for disease targets; development across diverse therapeutic areas. - Liver-targeted delivery platform: proprietary delivery technology to enhance hepatic uptake and therapeutic efficacy of oligonucleotide drugs, supporting multiple candidates in preclinical and clinical stages. - Drug discovery and development services: in-house R&D capabilities for target validation, preclinical pharmacology, toxicology studies, formulation development, and scalable manufacturing processes. - Clinical development and regulatory support: planning and execution of Phase I–III programs, with strategy for global regulatory submissions and earlier-phase regional trials. Latest major company changes: - Strategic listing and capitalization: lists on the Main Board of the Hong Kong Stock Exchange (ticker HK: 06938) in January 2026, underscoring a transition to a publicly traded, globally visible platform for its oligonucleotide therapeutics portfolio. - Pipeline expansions and trial activity: announcements of expanded delivery capabilities and multi-organ targeting (RiboPepstar delivery platform enhancements enabling broader tissue distribution for siRNA therapies), with subsequent Phase 2/3 trial applications and ongoing clinical program updates through 2026. - Management and organizational updates: executive appointments and governance enhancements aligned with rapid clinical development and international collaboration strategies in early 2026. - Geographic and operational expansion: continued investment in scalable manufacturing capabilities and international trial collaborations to support a growing global development footprint. Industry and segments: - Industry: biotechnology, focused on oligonucleotide therapies and RNA interference. - Segments: research and development of siRNA drugs; antisense and aptamer therapeutics; liver-targeted drug delivery; clinical development services; contract research and collaboration opportunities. Geographic operations: - Headquarters: Suzhou, China. - Global footprint: active collaborations and clinical development programs with international partners, and plans for global regulatory filings and market access, reflecting a global development and potential commercialization strategy. Corporate structure: - Founding year and history: established in 2007, with growth into a publicly listed company on the Hong Kong Stock Exchange in 2026. - Subsidiaries and alliances: maintains collaboration arrangements and strategic partnerships to advance its RNAi pipeline and delivery technologies, with emphasis on expanding indications and regional development programs. Note: The company emphasizes its proprietary RiboGalSTAR liver-targeted delivery platform and a diversified pipeline across cardiovascular, metabolic, renal, and hepatic diseases, positioning it as a global player in next-generation oligonucleotide therapeutics. The information reflects public disclosures and company materials through 2026.